|Application ||WB, IF, ICC, E|
|Other Accession||AF012536, 2338421|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||65 kDa|
|Application Notes||DcR1 antibody can be used for detection of DcR1 by Western blot 0.5 µg/mL. An approximate 65 kDa band can be detected. Antibody can also be used for immunocytochemistry starting at 10 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Other Names||DcR1 Antibody: LIT, DCR1, TRID, CD263, TRAILR3, TRAIL-R3, DCR1-TNFR, LIT, UNQ321/PRO366, Tumor necrosis factor receptor superfamily member 10C, Decoy TRAIL receptor without death domain, DcR1, tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain|
|Reconstitution & Storage||DcR1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||DcR1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||DCR1, LIT, TRAILR3, TRID|
|Function||Receptor for the cytotoxic ligand TRAIL. Lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. May protect cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.|
|Cellular Location||Cell membrane; Lipid-anchor, GPI-anchor.|
|Tissue Location||Higher expression in normal tissues than in tumor cell lines. Highly expressed in peripheral blood lymphocytes, spleen, skeletal muscle, placenta, lung and heart|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DcR1 Antibody: Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumor cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL. Two decoy receptors for TRAIL have been identified and designated DcR1/TRID/TRAIL-R3/LIT and DcR2/TRAIL-R4/TRUNDD. DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycophospholipid-anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues but not in most cancer cell lines. Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis.
Pan G; O'Rourke K; Chinnaiyan et al.. The receptor for the cytotoxic ligand TRAIL. Science; 1997;276:111-113
Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-8
Sheridan JP, Marsters SA, Pitti RM, et al. A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21
Degli-Esposti MA, Smolak PJ, Walczak H, et al, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186(7):1165-70
If you have any additional inquiries please email technical services at firstname.lastname@example.org.